1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction
04. Dezember 2023 07:07 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Appoints Larry Firestone as Chairman and CEO
29. November 2023 07:07 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (“22nd Century” or the “Company”), a biotechnology company focused on utilizing advanced plant technologies...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise
27. November 2023 16:44 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Nov. 27, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company” or “22nd Century”), a leading biotechnology company focused on utilizing advanced plant...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores
08. November 2023 13:15 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License
07. November 2023 08:45 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results
06. November 2023 07:30 ET | 22nd Century Group, Inc
Third quarter 2023 net revenue of $17.8 millionExpanded VLN® availability to more than 4,550 stores in 19 statesProposed FDA menthol ban regulation now undergoing review at OMBGVB bulk ingredient...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Reduces Debt by $8.1 Million
25. Oktober 2023 09:00 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Announces Pricing of $5.25 Million Public Offering
17. Oktober 2023 09:15 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco,...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States
12. September 2023 07:00 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco Assets
05. September 2023 07:00 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Sept. 05, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ: XXII) (the “Company”) today announced that its Board of Directors, after consultation with its financial and legal...